BR112018067969A2 - uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica - Google Patents

uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica

Info

Publication number
BR112018067969A2
BR112018067969A2 BR112018067969A BR112018067969A BR112018067969A2 BR 112018067969 A2 BR112018067969 A2 BR 112018067969A2 BR 112018067969 A BR112018067969 A BR 112018067969A BR 112018067969 A BR112018067969 A BR 112018067969A BR 112018067969 A2 BR112018067969 A2 BR 112018067969A2
Authority
BR
Brazil
Prior art keywords
stem cells
dental pulp
neurological disease
compositions
hydpss
Prior art date
Application number
BR112018067969A
Other languages
English (en)
Inventor
Valverde Wenceslau Cristiane
Kerkis Irina
Original Assignee
Avita Int Ltd
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/065,259 external-priority patent/US11207352B2/en
Application filed by Avita Int Ltd, Fund Butantan filed Critical Avita Int Ltd
Publication of BR112018067969A2 publication Critical patent/BR112018067969A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)

Abstract

a invenção fornece composições farmacêuticas compreendendo células estaminais de polpa dentária imaturas humanas (hidpscs), em que as hidpscs expressam cd44 e cd13. a invenção também fornece métodos de tratamento de uma doença ou condição neurológica compreendendo administrar sistemicamente a um indivíduo uma composição farmacêutica compreendendo hidpscs, em que as hidpscs expressam cd44 e cd13. por exemplo, para o tratamento de doenças ou condições neurológicas, incluindo o suporte ao mecanismo de neuroproteção em indivíduos diagnosticados com hd inicial ou a reparação de neurônios da perdidos em indivíduos diagnosticados com dp.
BR112018067969A 2016-03-09 2017-03-09 uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica BR112018067969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/065,259 US11207352B2 (en) 2013-03-15 2016-03-09 Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease
PCT/IB2017/051404 WO2017153956A1 (en) 2016-03-09 2017-03-09 Uses of dental pulp stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease

Publications (1)

Publication Number Publication Date
BR112018067969A2 true BR112018067969A2 (pt) 2019-01-15

Family

ID=58387859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067969A BR112018067969A2 (pt) 2016-03-09 2017-03-09 uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica

Country Status (9)

Country Link
EP (2) EP3426770A1 (pt)
JP (2) JP6997716B2 (pt)
KR (2) KR102497999B1 (pt)
CN (2) CN109219441B (pt)
BR (1) BR112018067969A2 (pt)
CA (2) CA3055399A1 (pt)
IL (2) IL261622B2 (pt)
RU (2) RU2742828C2 (pt)
WO (2) WO2017153956A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630133A4 (en) * 2017-05-26 2021-01-20 Steminent Biotherapeutics Inc. POLYGLUTAMINE DISEASE THERAPY (POLYQ)
IL280387B1 (en) * 2018-07-31 2024-03-01 Japan Chem Res A method for producing cells derived from dental pulp
WO2020212418A1 (en) * 2019-04-15 2020-10-22 Nanologica Ab Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia.
CN110179827A (zh) * 2019-06-27 2019-08-30 北京三有利和泽生物科技有限公司 牙源性间充质干细胞的应用
CN110314172A (zh) * 2019-07-17 2019-10-11 中国医科大学附属第一医院 一种用于治疗脊髓损伤的细胞制剂及其制备方法
EP4130240A4 (en) * 2020-03-31 2024-05-08 Cell Exosome Therapeutics Inc. METHOD FOR PRODUCING PROLIFERATIVE CELLS, METHOD FOR PRODUCING CELLULAR PRODUCT, POPULATION OF MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING SAME, SUPERNAtant OF STEM CELL CULTURE AND METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT
CN111973631A (zh) * 2020-08-21 2020-11-24 卡替(上海)生物技术有限公司 牙髓间充质干细胞在制备阿尔茨海默病治疗药物中的用途
CN115192609A (zh) * 2022-05-10 2022-10-18 湖南中南大学湘雅口腔医院 间充质干细胞在制备治疗抑郁症的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101243178A (zh) 2005-06-16 2008-08-13 特拉维夫大学拉莫特有限公司 用于治疗cns疾病的分离细胞和包含这种细胞的细胞群
WO2008080200A1 (en) * 2006-12-29 2008-07-10 Irina Kerkis Process for obtaining stem cells
ATE530638T1 (de) 2007-04-26 2011-11-15 Univ Ramot Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut
RU2347579C1 (ru) * 2007-07-03 2009-02-27 Общество с ограниченной ответственностью "Медицинские технологии" Способ получения клеточной культуры для лечения сосудистых и демиелинизирующих заболеваний нервной системы и клеточная культура, полученная этим способом (варианты)
WO2009072527A1 (ja) * 2007-12-05 2009-06-11 National University Corporation Nagoya University 歯髄幹細胞を用いた自家又は同種移植用組成物及びその用途
JP5621105B2 (ja) * 2008-03-12 2014-11-05 公益財団法人ヒューマンサイエンス振興財団 根管充填材
DK2620493T3 (da) 2008-05-28 2019-07-01 Univ Ramot Mesenkymale stamceller til behandling af CNS-sygdomme
ITRM20080342A1 (it) * 2008-06-26 2009-12-27 Univ Degli Studi Udine Cellule di polpa dentale midollo-simili, metodi per isolamento ed uso.
CN102725398B (zh) * 2009-12-21 2014-01-08 学校法人总持学园鹤见大学 用于培养及保存牙髓细胞的离体牙的移送方法
EP2680864B1 (en) 2011-03-03 2019-05-08 Ramot at Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
WO2013076726A1 (en) 2011-11-21 2013-05-30 Ramot At Tel-Aviv University Ltd. Stem cell-derived neural cells for cell therapy in neurological disorders
EP2633870B1 (en) * 2012-02-29 2018-08-01 Technische Universität Berlin Method of preparing an artificial tooth primordium in vitro and artificial tooth primordium derived therefrom
US9790468B2 (en) * 2013-03-15 2017-10-17 Avita Iinternational Ltd. Multifunctional immature dental pulp stem cells and therapeutic applications

Also Published As

Publication number Publication date
CN109312303A (zh) 2019-02-05
IL261622B1 (en) 2023-05-01
EP3426267B1 (en) 2023-01-11
JP6997716B2 (ja) 2022-02-04
RU2018134710A3 (pt) 2020-06-25
KR102497999B1 (ko) 2023-02-08
JP2019507772A (ja) 2019-03-22
BR112018067971A2 (pt) 2019-01-15
IL261622A (en) 2018-10-31
CA3055399A1 (en) 2017-09-14
CN109312303B (zh) 2024-03-26
IL261623A (en) 2018-10-31
CA3055398A1 (en) 2017-09-14
CN109219441A (zh) 2019-01-15
WO2017153957A9 (en) 2017-11-02
KR20190003489A (ko) 2019-01-09
JP2019510758A (ja) 2019-04-18
IL261623B2 (en) 2024-03-01
IL261623B1 (en) 2023-11-01
WO2017153957A1 (en) 2017-09-14
RU2018134710A (ru) 2020-04-09
RU2741839C2 (ru) 2021-01-29
RU2018134615A3 (pt) 2020-07-28
EP3426770A1 (en) 2019-01-16
KR102363146B1 (ko) 2022-02-14
WO2017153956A1 (en) 2017-09-14
KR20180137488A (ko) 2018-12-27
CN109219441B (zh) 2022-06-10
RU2742828C2 (ru) 2021-02-11
IL261622B2 (en) 2023-09-01
RU2018134615A (ru) 2020-04-10
EP3426267A1 (en) 2019-01-16
JP7008031B2 (ja) 2022-02-10

Similar Documents

Publication Publication Date Title
BR112018067969A2 (pt) uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
BR112018068066A2 (pt) compostos bicíclicos para diagnóstico e terapia
BR112014027155A2 (pt) composições de celúlas t deficientes do re-ceptor de células t
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
DOP2011000045A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
WO2017062456A3 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
AR101236A1 (es) Composiciones para el cuidado oral
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112021017436A2 (pt) Composições farmacêuticas para tratamento de doenças ou transtornos oculares
BR112017008805A2 (pt) tratamento de córnea usando laminina
BR112022010411A2 (pt) Composições bacterianas projetadas e usos das mesmas

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/03/2017, OBSERVADAS AS CONDICOES LEGAIS